Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma
Phase III Randomized Study Of Gemcitabine Versus Gemcitabine-Oxaliplatine In Patients With Locally Advanced Or Metastatic Pancreatic Carcinoma
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Listed as NCT00075452, this PHASE3 trial focuses on Pancreatic Cancer and remains ongoing. Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group, it has been updated 7 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2018 [monthly]
Unknown Status PHASE3
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Beauvais, France , Bordeaux, France , Boulogne-Billancourt, France , Briis-sous-Forges, France , Chartres, France , Clermont-Ferrand, France , Clichy, France , Colombes, France , Dijon, France and 20 more locations